Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross‐Sectional Study Authors: Shiv Kumar Sah, Ashok Kumar Gupta, Sanjaya Acharya, Suraj Kumar Thakur, Rajkumar Chaudhary, Shiva Pandeya, Arjun Budthapa, Vijaya K C, Sajish Khadgi, Manjita Bajracharya Published: 2026 ABSTRACT ABSTRACTBackground and AimsEpistaxis is a common complication associated with oral anticoagulant and antiplatelet therapies, often leading to significant morbidity. In recent years, the incidence of cardiovascular disease in Nepal has risen dramatically, driving a widespread use of these medications and heightened concerns regarding bleeding complications. Despite this growing concern, epidemiological data on epistaxis in the Nepalese population is rarely documented. This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelets at a tertiary care hospital in Nepal.MethodsA cross‐sectional study was conducted among 284 patients receiving oral anticoagulants at a tertiary care hospital over a 1‐year period. Data were collected through structured interviews and medical record reviews. The prevalence of epistaxis with corresponding 95% CI was calculated, and risk factors were analyzed using multivariate logistic regression. A receiver operating characteristic (ROC) curve was determined to establish the suitability of the model.ResultsOf the 284 patients, 23.2% (95% CI: 18.4%–28.5%) experienced epistaxis, with 23.2% (95% CI: 18.4%–28.5%) of cases classified as moderate in severity. In multivariate model, age (as continuous) (AOR: 1.068; 95% CI: 1.009–1.13), age (category) ≥ 60 years (AOR: 6.21; 95% CI: 1.20–32.16), male gender (AOR: 1.87; 95% CI: 1.032–3.41), rural residency (AOR: 1.96; 95% CI: 1.04–3.71), having Congestive heart failure (AOR: 2.38; 95% CI: 1.012–5.62), being hypertensive (AOR: 3.14; 95% CI: 1.50–6.53), and individuals on warfarin therapy (AOR: 3.14; 95% CI: 1.50–6.53) emerged as independent predictors associated with the increased risk for experiencing epistaxis. The model revealed a good applicability (AUC: 0.71; 95% CI: 0.64–0.78).ConclusionEpistaxis remained a common complication among patients receiving oral anticoagulant therapy in Nepal, with advancing age, male gender, rural residency, hypertension, congestive heart failure, and warfarin therapy identified as significant risk factors. These findings underscore the need for enhanced patient monitoring and tailored care plans to mitigate bleeding risks in high‐risk groups.Keywords: antiplatelet, epistaxis, Nepal, oral anticoagulants, prevalence, risk factors, warfarin Introduction Epistaxis, an acute bleeding of nose, nasal cavity, or nasopharynx [1], is a common medical condition that can range from minor nuisance to severe, life–threatening bleeding necessitating immediate medical attention [2]. This also presents a significant challenge to otolaryngologists, as it can frequently cause distress for both patients and clinicians, particularly when the bleeding persists for more than an hour [3]. This condition is recognized as an otorhinolaryngologic emergency, requiring prompt intervention in both the Accident and Emergency Department and the Ear, Nose, and Throat (ENT) Department [2, 4]. It is estimated that up to 60% of the general population experience at least one episode of epistaxis during their lifetime, with approximately 6% seeking medical attention for the condition [5]. Furthermore, studies indicate that annually, between 7% and 14% of the general population is admitted to emergency departments due to epistaxis [6, 7]. While epistaxis can occur due to several factors either local or systemic factors [8, 9, 10], patients taking oral anticoagulants and antiplatelet medications are at a higher risk due to the blood‐thinning properties of these drugs [8]. These medications, widely prescribed for the prevention and treatment of cardiovascular diseases such as atrial fibrillation, venous thromboembolism, and ischemic heart disease [11, 12, 13, 14], can impair hemostasis and lead to complications, including prolonged bleeding, making their management complex when bleeding episodes occur. Epistaxis in such patients poses unique challenges, particularly in balancing the risks of bleeding with the benefits of continued anticoagulation. This issue is especially pertinent in resource‐limited settings like Nepal, where healthcare systems may face constraints in managing complications related to anticoagulant and antiplatelet therapies. Notably, the global and national rise in cardiovascular diseases [15, 16], has led to the widespread use of these medications [17], raising concern about the growing risk of bleeding complications. Despite the global awareness of such bleeding risks, there is a paucity of robust epidemiological data from developing countries, particularly in Nepal, regarding the prevalence and risk factors for epistaxis in this patient population. Therefore, this study aims to assess the prevalence of epistaxis in patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal and identify the key demographic and clinical factors associated with its occurrence. By understanding these factors, clinicians can better anticipate which patients are at heightened risk for epistaxis, leading to more individualized treatment approaches and preventive strategies. Methods Study Design and Duration This study employed a hospital‐based observational, cross‐sectional design to determine the prevalence of epistaxis and identify the associated factors among patients on oral anticoagulants and antiplatelet medications at a tertiary care hospital in Nepal. The study was conducted at the Department of Emergency and the Ear, Nose, and Throat (ENT) over a 1‐year period, from November 2023 to October 2024. Study Setting and Justification The study was conducted at the Department of Emergency and ENT of Tribhuvan University Teaching Hospital (TUTH), Institute of Medicine (IOM), a tertiary care hospital of Nepal's premier healthcare institutions, situated in the heart of the capital city, Kathmandu. TUTH stands as the top referral hospital in the country and a public hospital in Kathmandu with 850 beds, which is recognized hospitals of Nepal with a good flow of patients from all over Nepal, making it easier to recruit a sufficient number of representing cases for the study. This hospital serves a diverse patient population across the country from both urban and rural areas, making an ideal setting for the representative samples to study on the prevalence and risk factors associated with epistaxis in patients taking anticoagulants and antiplatelet medications. Study Population and Selection Criteria Inclusion and Exclusion Criteria The study included individuals aged 40 years or older who had been prescribed oral anticoagulants or antiplatelet agents for at least 3 months. Patients were excluded if they had a known bleeding disorder unrelated to the use of anticoagulant or antiplatelet medication, a history of coagulopathy or other bleeding disorders (e.g., hemophilia), recent craniofacial or nasal trauma or surgery within the past 6 months, a known history of nasal polyps or other nasal lesions, or if they declined to provide consent. Variables of Interest In this study, age, gender, residency, social habits, underlying medical conditions, types of anticoagulant and antiplatelet medications, and the duration of medication use were identified as exposure variables; whereas the prevalence, severity, and frequency of epistaxis were evaluated as outcome variables. Sample Size Determination The sample size was determined using a Cochrane formula for cross‐sectional studies [18]: where Z is the Z‐value corresponding to a 95% confidence level (1.96), P is the estimated prevalence of epistaxis in patients on anticoagulants/antiplatelet, based on previous, and d is the margin of error, set at 5%. Assuming an estimated prevalence of epistaxis of 21% [19] and a 10% non‐response rate, the final sample size was calculated to be 284 patients. Sampling Method Patients were recruited through consecutive sampling from outpatient departments (ENT and Emergency) and inpatient wards. Recruitment continued until the calculated sample size was achieved. Data Collection Tool and Technique Data were collected using a structured, pre‐tested questionnaire administered through face‐to‐face interviews by trained research assistants, researcher, and clinician involved in the study. Data Collection Procedure The study initially identified potential participants from patients currently prescribed anticoagulant and antiplatelet medications who were visiting the ENT and Emergency Departments at TUTH. Informed consent was obtained from each participant prior to data collection. Socio‐demographics, including age, gender, occupation, place of residence, and lifestyle factors such as smoking and alcohol use were gathered. Relevant medical history was obtained from patient medical records, and, when necessary, interviews were conducted with patients or their relatives to gather information on comorbidities, history of epistaxis, frequency and severity of epistaxis, other bleeding episodes, and underlying medical conditions; Medication details, including Information on the types of medications and the duration of anticoagulant or antiplatelet therapy, which were obtained from medical and prescription records; clinical examination: A focused nasal examination was performed by an ENT specialist to assess for predisposing factors such as nasal septal deviation, mucosal dryness, and the presence of nasal polyps or other abnormalities. Classification of Severity of Epistaxis All these patients were categorized in three groups of mild, moderate, severe, and very severe epistaxis on the basis of assumption of blood loss in mL and estimation of Hb%, as well as clinical judgment. Urban vs. Rural The classification of study areas as urban or rural followed the official administrative categorization of Nepal. Individuals residing in metropolitan, sub‐metropolitan, and municipal areas were defined as urban residents, whereas those residing in rural municipalities were defined as rural residents. Reliability and Validity of the Study Inter‐Rater Reliability For data involving subjective assessments, such as patient‐reported severity of epistaxis, two independent reviewers evaluated the records to ensure consistency. Validity Content Validity The questionnaire was developed in consultation with clinical experts and based on a thorough review of the literature. It covered all relevant aspects related to epistaxis and its risk factors in the context of antiplatelet therapy. Face Validity A pilot study was conducted with 20 patients to ensure that the questionnaire was clear and comprehensible. Feedback was incorporated to refine the final version. Construct Validity Logistic regression analysis was used to verify that the associations between epistaxis and potential risk factors (e.g., age and duration of therapy) were consistent with theoretical expectations based on prior research. Further, Hosmer–Lemeshow test and ROC curve were plotted to support the validity and reliability of our logistic regression model. Criterion‐Related Validity The findings were compared with established benchmarks from similar studies conducted in other populations, confirming that the prevalence and associated risk factors were whether or not in line with previously reported results. Statistical Analysis Guidelines for Reporting of Statistics for Clinical Research in Urology by Assel et al. [20] were adhered to ensure that the statistical analysis, presentation of data, and interpretation of results in our study follow the established best practices in clinical research. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. The distribution of continuous variables was assessed using the Kolmogorov–Smirnov test. Variables that were normally distributed are presented as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages. Bivariate analyses were conducted to explore associations between epistaxis and categorical variables using Chi‐square tests or Fisher's exact tests, as appropriate, and independent t‐tests or Mann–Whitney U tests were used for continuous variables. Variables with a p‐value < 0.05 in bivariate analysis were included in the logistic regression model. Crude and Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were reported to identify the independent factors associated with the epistaxis. All tests are two‐sided, and a p‐value < 0.05 was considered statistically significant in all analyses. All statistical analyses were conducted using SPSS, version 23. The Hosmer–Lemeshow goodness‐of‐fit test was used to test model fitness. Additionally, a receiver operating characteristic (ROC) curve was also generated to assess suitability of the model. A model is considered good if the area under the curve (AUC) exceeds 0.7, with values between 0.87 and 0.9 indicating strong discrimination, and an AUC above 0.9 reflecting excellent performance. Ethical Considerations The study was approved by the Institutional Review Committee (IRC‐IOM), Institution of Medicine, Tribhuvan University prior to the commencement of the study (Reference no. 263(6‐11) E2, 080/081). Written informed consent was obtained from all participants before data collection. Confidentiality and privacy were ensured by anonymizing patient data and securing the database. Only the research team had access to the data. Patients who experienced active epistaxis during the study were provided with appropriate medical care, as per hospital protocol. Results Table 1 depicts the baseline data (socio‐demographics and clinical characteristics) of the study population. The mean age of the subjects was 62.7 ± 9.1 years, with a minimum of 42 and a maximum of 82 years, with a slight predominance of male (51.4%). The majority of patients (43.3%) belonged to the age group of 60–69 years. More than half (56.3%) of the patients were from urban areas. TABLE 1Baseline characteristics of the study participants.ParametersInferencesPopulation size, n 284 A.Demographic characteristics Age (continuous) mean ± SD, (min–max)62.7 ± 9.1 (minimum: 42–maximum: 82)Age group, n (%)40–4930 (10.6)50–5971 (25.0)60–69123 (43.3)70+60 (21.1)Gender, n (%)Male146 (51.4)Female138 (48.6)Residential area, n (%)Rural160 (56.3)Urban124 (43.7)Occupational status, n (%)Unemployed/housemaker60 (21.1)Self employed72 (25.4)Employed49 (17.3)Wage earner30 (10.6)Retired73 (25.7) B.Life style and habit Smoking status, n (%)Non smoker150 (52.8)Current smoker93 (32.7)Ex‐smoker41 (14.4)Alcohol consumption status, n (%)Non‐drinker138 (48.6)Former drinker42 (14.8)Current moderate drinker89 (31.3)Current heavy drinker15 (5.3) C.Clinical characteristics Underlying medical condition, n (%)Peripheral vascular disease43 (15.1)Cerebrovascular disease89 (31.3)Coronary artery disease102 (35.9)Congestive heart failure30 (10.6)Arrhythmia20 (7.0)Comorbidity, n (%)Hypertension57 (20.0)Diabetes mellitus73 (25.7)Hypothyroidism23 (8.2)Hyperlipidemia2 (0.7)Hypertension + diabetes mellitus77 (27.1)Hypertension + asthma7 (2.5)Hypertension + asthma + diabetes mellitus14 (4.9)Hypertension + hyperthyroidism6 (2.1)Diabetes mellitus + hyperlipidemia13 (4.6)Hypertension + diabetes mellitus + hyperlipidemia12 (4.2)Duration of medication, n (%)3–6 months109 (38.4)6 months–1 year97 (34.2)> 1 year78 (27.5)Medication prescribedAnticoagulant, n (%)100 (35.2) a.Classical oral anticoagulant (COAC) i. Warfarin42 (14.8) b.Newer oral anticoagulant (NOAC) 58i. Dabigatran30 (10.6)ii. Apixaban11 (3.9)iii. Rivaroxaban17 (6.6)Antiplatelet, n (%)130 (45.8)Aspirin85 (29.9)Clopidogrel45 (15.84)Combination drugs54 (19.01)Warfarin + aspirin33 (11.6)Warfarin + clopidogrel8 (2.8)Aspirin + clopidogrel13 (4.6) Baseline characteristics of the study participants. A.Demographic characteristics A.Demographic characteristics Demographic characteristics B.Life style and habit B.Life style and habit Life style and habit C.Clinical characteristics C.Clinical characteristics Clinical characteristics a.Classical oral anticoagulant (COAC) a.Classical oral anticoagulant (COAC) Classical oral anticoagulant (COAC) b.Newer oral anticoagulant (NOAC) b.Newer oral anticoagulant (NOAC) Newer oral anticoagulant (NOAC) In terms of social habits, approximately half of the population were non‐smokers (52.8%) and non‐drinkers (48.6%). Conversely, current smoking and moderate drinking were recorded in about one‐third of the population. Regarding medical history, cerebrovascular disease and coronary artery disease were observed in roughly one‐third of the patients, followed by peripheral vascular disease (15.1%), congestive heart failure (10.6%), and arrhythmia (7%). Diabetes mellitus and hypertension were the most common comorbidities, found in 25.7% and 20% of the population, respectively, while the combination of diabetes and hypertension was present in 27.1% of the patients. Aspirin and warfarin were prescribed to 29.9% and 14.8% of patients, respectively, with 11.6% of patients receiving a combination of both aspirin and warfarin. Table 2 summarizes the prevalence rate, severity, and the frequency of epistaxis episodes in the study population. The overall prevalence rate of the epistaxis was 23.2% (95% CI: 18.4%–28.5%). Among the affected individuals, the majority exhibited moderate severity of symptoms, accounting for 43.9% of the cases (95% CI: 31.7%–56.7%). As far as frequency concerned, nearly half of the patients experienced occasional episodes of epistaxis, with a reported prevalence of 45.4% (95% CI: 33.1%–58.1%). TABLE 2Prevalence, severity, and frequency of epistaxis episodes.FrequencyPrevalence (%) (95% CI: LL–UL)Epistaxis (n = 284)Present6623.2 (18.4–28.5)Severity (n = 66)Mild1015.15 (7.5–26.1)Moderate2943.93 (31.7–56.7)Severe1827.27 (17.0–39.6)Very severe913.63 (6.4–24.3)Frequency (n = 66)Rarely1725.7 (15.7–38.0)Occasionally3045.4 (33.1–58.1)Frequently1928.8 (18.3–41.2) Prevalence, severity, and frequency of epistaxis episodes. Table 3 demonstrates the results of bivariate analysis (Chi‐square tests for categorical variables, while independent t‐tests for continuous variables) to examine the association between epistaxis and a set of potential predictor variables. Patients with epistaxis had a significantly higher mean age compared to those without episodes of epistaxis (61.73 ± 9.21 years vs. 10 ± 8.22 years; t = 11.95; p < 0.05). The prevalence of epistaxis was notably higher among older individuals, particularly in the age groups of 60–70 years (51.5%) and above 70 years (48.8%), in comparison to younger age groups (χ 2 = 10.009, p = 0.018, 95% CI). Gender was also a significant factor, with males showing a higher prevalence of epistaxis (62.1%) than females (37.9%) (χ 2 = 3.950, p = 0.047). Additionally, patients living in rural areas exhibited a higher prevalence of epistaxis (68.2%) compared to those residing in urban areas (31.8%) (χ 2 = 4.903, p = 0.027). Smoking status was another significant predictor, with current smokers having a higher prevalence of epistaxis (42.4%) compared to non‐smokers (39.4%) and ex‐smokers (13.3%) (χ 2 = 6.22; p < 0.05). Clinically, conditions such as congestive heart failure (χ 2 = 5.28; p < 0.05), hypertension (χ 2 = 4.07; p < 0.05) were significantly associated with the occurrence of epistaxis. Additionally, the use of anticoagulant and antiplatelet medications, such as warfarin (χ 2 = 4.30; p < 0.05) and clopidogrel (χ 2 = 4.4, p < 0.05) demonstrated a significant correlation with epistaxis. TABLE 3Association between epistaxis and predictor variables.ParametersPresentAbsentTest p valueAge66.10 ± 8.2261.73 ± 9.21 t = 11.95< 0.001Age (cat) χ 2 = 10.0090.018340–493 (4.5)27 (12.4)50–5910 (15.2)61 (28.0)60–6934 (51.5)89 (40.8)70+19 (28.8)41 (18.8)Gender χ 2 = 3.940.047Male41 (62.1)105 (48.2)Female25 (37.9)113 (51.8)Residential area0.027Rural45 (68.2)115 (52.8)Urban21 (31.8)103 (47.2)Occupational status χ 2 = 7.410.112Unemployed/housemaker17 (25.8)43 (19.7)Self employed20 (30.3)52 (23.9)Employed5 (7.6)44 (20.2)Wage earner5 (7.6)25 (11.5)Retired19 (28.8)54 (24.8)B. Life style and habitSmoking status χ 2 = 6.220.044Non smoker26 (39.4)124 (56.9)Current smoker28 (42.4)65 (29.8)Ex‐smoker12 (18.2)29 (13.3)Alcohol consumption status χ 2 = 6.250.100Non‐drinker25 (37.9)113 (51.8)Current moderate drinker26 (39.4)63 (28.9)Current heavy drinker6 (9.1)6 (4.1)Former drinker9 (13.6)33 (15.1)Underlying medical conditionPeripheral vascular disease χ 2 = 0.150.691Present11 (16.7)32 (14.7)Absent55 (83.3)186 (85.3)Coronary artery disease χ 2 = 3.850.052Present17 (25.8)85 (39.0)Absent49 (74.2)133 (61.0)Cerebrovascular disease χ 2 = 0.0430.834Present20 (30.3)69 (31.7)Absent46 (69.7)149 (68.3)Congestive heart failure (CHF) χ 2 = 5.280.022Present12 (18.2)18 (8.3)Absent54 (81.8)200 (91.7)ComorbidityHypertension χ 2 = 4.070.044Present47 (71.2)38 (17.4)Absent19 (28.8)180 (82.6)Diabetes mellitus χ 2 = 1.620.200Present13 (19.7)60 (27.5)Absent53 (80.3)158 (72.5)Hypertension + diabetes χ 2 = 0.960.321Present21 (31.8)56 (25.7)Absent45 (68.2)162 (74.3)Duration of medication χ 2 = 6.390.0413–6 months17 (25.8)92 (42.2)6 months–1 year25 (37.9)72 (33.0)More than 1 year24 (36.4)54 (24.8) χ 2 = 0.430.514Oral anticoagulants (any)Yes21 (31.8)79 (36.2)No45 (68.2)139 (63.8)Warfarin χ 2 = 4.300.038Yes15 (22.7)27 (12.4)No51 (77.3)191 (87.6)Dabigatran χ 2 = 0.650.193Yes6 (9.1)24 (11.0)No60 (90.9)194 (89.0)Antiplatelet (any) χ 2 = 0.820.362Yes27 (40.9)103 (47.2)No39 (59.1)15 (52.8)Aspirin χ 2 = 0.990.315Yes23 (34.8)62 (28.4)No43 (65.2)62 (28.4)ClopidogrelYes5 (7.6)40 (18.3) χ 2 = 4.40.036No61 (92.4)178 (81.7)Warfarin + aspirin χ 2 = 2.11Yes11 (16.7)22 (10.1)0.142No55 (83.3)196 (89.9)Warfarin + any antiplatelet χ 2 = 1.90.164Yes13 (19.728 (12.8)No53 (80.3)190 (87.2) Association between epistaxis and predictor variables. Table 4 illustrates the results of univariate and multivariate analyses of factors associated with episodes of epistaxis. In the univariate analysis, factors such as age as continuous (COR: 1.058; p < 0.05), age group ≥ 60years (COR: 3.66; p < 0.05), male gender (COR:1.76; p < 0.05), residence in rural areas (COR:1.91; p < 0.05), current smoking status (COR:2.054; p < 0.05), the presence of congestive heart failure (CHF), hypertension (COR: 1.91; p < 0.05), long‐term use (over 1 year) of antiplatelet or anticoagulant medications (COR:2.40; p < 0.05), use of warfarin (UOR:2.081; p < 0.05), and clopidogrel (COR:0.36; p < 0.05) were all identified as the risk factors associated with the increased risk for developing epistaxis episode. TABLE 4Univariate and multivariate logistic regression for the factors associated with the episode of epistaxis.ParametersCOR (95% CI) p valueAOR (95% CI) p valueAge (continuous)1.058 (1.023–1.093)0.0011.068 (1.009–1.13)0.023Age (category)40–49Reference50–591.47 (0.37–5.79)0.572.1 (0.50–9.30)0.29≥ 603.66 (1.067–12.61)0.0296.21 (1.20–32.16)0.039GenderMale vs. female1.765 (1.004–3.102)0.0481.87 (1.032–3.41)0.039Residential areaRural vs. urban1.919 (1.072–3.436)0.0271.96 (1.04–3.71)0.037Smoking statusNon smokerReferenceCurrent smoker2.054 (1.114–3.790)0.0210.72 (0.28–1.89)0.51Ex‐smoker1.973 (0.892–4.368)0.0941.04 (0.40–2.71)0.92Congestive heart failurePresent vs. absent2.469 (1.121–5.440)0.0252.38 (1.012–5.62)0.047HypertensionPresent vs. absent1.915 (1.012–3.622)0.0463.14 (1.50–6.53)0.002Duration of medication3–6 monthsReference6 months–1 year1.879 (0.943–3.743)0.0730.98 (0.32–2.57)0.98More than 1 year2.405 (1.187–4.874)0.0151.14 (0.35–3.64)0.82WarfarinReceived vs. not received2.081 (1.030–4.201)0.0412.38 (1.10–5.14)0.022ClopidogrelReceived vs. not received0.36 (0.13–0.96)0.0420.41 (0.14–1.79)0.099 Note: CHF, congestive heart failure. Univariate and multivariate logistic regression for the factors associated with the episode of epistaxis. Note: CHF, congestive heart failure. After adjusting for all these significant factors in the multivariate analysis, age (as continuous) (AOR: 1.068; 95% CI: 1.009–1.13), age (cat) ≥ 60 years (AOR: 6.21; 95% CI: 1.20–32.16), male gender (AOR: 1.87; 95% CI: 1.032–3.41), rural residence (AOR: 1.96; 95% CI: 1.04–3.71), having CHF (AOR: 2.38; 95% CI: 1.012–5.62), being hypertensive (AOR: 3.14; 95% CI: 1.50–6.53), and individuals on warfarin therapy (AOR: 3.14; 95% CI: 1.50–6.53) emerged as independent predictors associated with the increased risk for experiencing epistaxis episodes. The Hosmer–Lemeshow goodness‐of‐fit test showed a predicted value of 78.9% (χ 2 = 12.14; p = 0.14) indicating the robustness of our logistic regression model, and the area under the ROC curve (AUC) was 0.71; 95% CI: 0.64–0.78, suggesting that the model had good discriminatory ability (Figure 1). Receiving operating characteristic (ROC) curve for robustness of the model. The model demonstrated modest discriminatory performance (AUC = 0.71), suggesting that while it has acceptable predictive capability, there remains scope for improvement with inclusion of additional predictors or larger sample size. Table 5 summarizes the multicollinearity, assessed using the variance inflation factor (VIF) and tolerance among the predictor variables. Multicollinearity diagnostics indicated that all predictors had acceptable VIF values ranging from 1.18 to 2.11 (all < 5) and Tolerance values from 0.47 to 0.85 (> 0.1), suggesting no evidence of multicollinearity among the variables. TABLE 5Assessment of multicollinearity among predictor variables.Predictor variables β p ToleranceVIFAge0.2010.0250.4022.482Gender0.1000.0460.9141.081Congestive heart failure0.0910.1230.9131.091Hypertension0.1730.0120.7011.422Residential area0.1120.0480.9621.031Warfarin0.1630.0050.9641.033Duration of medication0.0160.8430.4612.142Smoking status0.0210.7440.7621.031Coronary artery disease−0.4820.4210.8901.113Comorbidities0.0330.6240.6831.462 Assessment of multicollinearity among predictor variables. Management of Epistaxis Cases Among the 66 cases of epistaxis examined, 38 cases (57.6%) were found to be self‐limiting and did not require any medical intervention. In contrast, 28 cases (42.4%) necessitated intervention, which was effectively managed through nasal packing (Supporting Information Figure S1). Discussion Epistaxis is one of the most common clinical entities, especially in patients on antiplatelet and anticoagulant therapy, responsible for admittance of patients to the ENT‐ED and has an important impact in healthcare costs [21]. This is especially true in resource‐limited countries like Nepal, where the use of these therapies is rising due to an increasing burden of cardiovascular diseases. The present study has uncovered several critical findings, including the prevalence rate of epistaxis and the factors contributing to its occurrence, which hold significant clinical implications. By unveiling the occurrence of bleeding episodes and examining the interplay between medication use and patient characteristics, this research seeks to fill an important gap in the current literature and inform healthcare providers operating in similar low‐resource settings. The identification of risk factors for epistaxis is a key outcome of this research, as it can aid in the development of targeted preventive measures. Globally, the prevalence of epistaxis in patients receiving antiplatelet and anticoagulant therapy varies considerably, generally ranging between 10% and 66.6% [22, 23, 24, 25] of all events, and 2%–5% for severe events [22, 23], depending on the population and type of therapy used. In this study, the prevalence was found to be 23.2%. This wide range of variability can be attributed to several factors, including the differences in the definition and classification of bleeding episodes, variation in the study design, patient's characteristics, presence of comorbidity, types of antithrombotic therapy, and the level of adherence to long‐term anticoagulation therapy. For instance, in a study by Buchberger et al. [25], 66.6% of all epistaxis cases occurred in patients undergoing anticoagulation therapy, with classic oral anticoagulants (COACs) being 3 times more common among these patients than newer‐generation oral anticoagulants (NOACs). This highlights the role that the type of anticoagulant plays in the incidence of bleeding events, with older anticoagulants potentially posing a higher risk compared to newer therapies. The prevalence shown in our study is somewhat comparable to the other studies conducted in resource‐rich nations [24, 26]. The similarities between Nepal's data and global figures suggest that despite Nepal's unique healthcare challenges, the biological risks associated with antithrombotic therapy are consistent across different populations. Regarding the severity of epistaxis, earlier studies have reported varying incidence rates. A study by Hollowel J et al. [24] found that the incidence of minor, referred, and fatal/hospitalized bleeding events was 18%, 19%, and 25%, respectively. A similar trend was observed in our study population. Specifically, 15% of patients experienced mild epistaxis, 44% had moderate cases, while 27% and 14% had severe and very severe episodes, respectively, necessitating immediate medical intervention. In this study, the mean age of participants presenting to the emergency and ENT departments was 62.7 ± 9.1 years (range: 42–82 years). This finding is comparable to previous studies, such as those by Buchberger et al. [25], but lower than the average age reported in other study settings [19, 27]. The difference in age distribution between our study and those conducted in more developed regions may reflect variations in patient demographics, healthcare access, and the prevalence of underlying comorbidities across different settings. In our study, the mean age of patients with epistaxis was significantly higher, at 66.10 ± 8.22 years, compared to those without epistaxis, whose mean age was 61.73 ± 9.21 years (p < 0.005). This finding is consistent with the study by Buchberger et al. [25], which reported a median age of 66.6 years for patients with epistaxis. However, our results indicate a slightly younger population compared to the median age of 72 years reported by J. Smith for patients experiencing epistaxis [19]. These findings also align with the results of Camacho Corte et al. [24], who also observed a significant age difference between patients with and without epistaxis. In their study, the mean age of the epistaxis group was 66 ± 18 years, while those without epistaxis had a mean age of 49 ± 19 years (p < 0.001) [27]. These consistent results across multiple studies suggest that older age is a significant risk factor for epistaxis, particularly in patients receiving antithrombotic therapy. Results of Multivariate analysis in the present study revealed that age emerged as an independent predictor of epistaxis episodes. Specifically, for each one‐unit increase in age, the risk of developing epistaxis increased by 6% (AOR: 1.068; p < 0.05). This finding is consistent with a growing body of research published elsewhere [8, 27, 28], which also highlights the significant association between advancing age and the likelihood of experiencing epistaxis, particularly in patients on antithrombotic therapy. These results underscore the importance of age as a key factor in assessing the risk of epistaxis, reinforcing the need for close monitoring and preventive measures for older populations, who are at higher risk for bleeding complications. Further, participants were categorized into three age groups—40–49 years, 50–59 years, and ≥ 60 years—to assess the age‐related susceptibility to epistaxis. The results multivariate analysis demonstrated a significant association between age group and the likelihood of experiencing epistaxis, with individuals aged ≥ 60 years showing markedly increased odds of developing the condition compared to those in the 40–49 years' age group. This finding is well‐supported by previous studies, which have also demonstrated an increased tendency for epistaxis with advancing age [27, 29]. These data emphasize the need for heightened vigilance and preventive strategies for older patients, particularly those over 60, who are at significantly greater risk of developing epistaxis, especially in the context of antithrombotic therapy. The increased incidence of epistaxis in the elderly is attributed to several factors, primarily degenerative changes in blood vessels such as fibrosis and scarring, which weaken vessel walls and impair their ability to contract, leading to prolonged bleeding [30]. Additionally, arteriosclerosis, a condition characterized by the thickening and hardening of the arterial walls, becomes more prevalent with age and increases the risk of epistaxis. The aging population is also more susceptible to various hemostatic disturbances, such as impaired blood clotting mechanisms, which further predispose them to nosebleeds [31]. These changes are further compounded by the use of antithrombotic medications, making epistaxis a common complication in older patients [32]. Moreover, Elderly patients are also more likely to have multiple comorbidities and take several medications, increasing the risk of drug interactions and adverse effects, including nosebleeds [33]. Our study revealed a significant association between gender and the occurrence of epistaxis, with a notably higher prevalence in males compared to females (62.1% vs. 37.9%; p < 0.05). This finding is consistent with a growing body of research conducted across various settings and populations, which also demonstrates a male predominance in epistaxis cases [34, 35, 36, 37]. Furthermore, multivariate analysis identified the male population as an independent factor associated with epistaxis. Specifically, the risk of developing nosebleeds in males was 1.87 times higher than that in females, highlighting gender as a significant determinant in the occurrence of this condition. The increased incidence of epistaxis in the male population can be attributed to several factors. One key factor is the protective role of the female sex hormone, estrogen [38], which helps maintain blood vessel and mucosal integrity. Estrogen promotes vasodilation, enhances blood vessel stability, and supports collagen production, reducing the likelihood of vessel rupture. In contrast, males, with lower estrogen levels, lack these protective effects, making their blood vessels more prone to damage and bleeding. Additionally, males are at higher risk for nasal trauma due to greater participation in physical activities, contact sports, and risky behaviors, all of which increase the likelihood of injury to the nasal passages. Hypertension, a well‐established risk factor for epistaxis [8, 39], is more prevalent in our male population. Elevated blood pressure places additional stress on fragile nasal capillaries, making them more susceptible to rupture. Furthermore, lifestyle factors such as smoking and alcohol consumption, which are linked to major bleeding [40], are more common among males, contribute to nasal mucosal dryness and damage, further increasing the risk of nosebleeds. These factors, combined, help explain the higher incidence of epistaxis in the male population. The prevalence of epistaxis can differ between rural and urban populations due to various environmental, lifestyle, and healthcare‐related factors. Studies have shown that geographical differences may influence the incidence and severity of epistaxis due to factors like climate, air quality, and access to medical care [41, 42]. In our study, individuals residing in rural areas exhibited a higher likelihood of experiencing epistaxis compared to their urban counterparts. The increased risk of epistaxis in rural residency could reflect limited access to healthcare, including the availability of otolaryngology (ENT) specialists, delayed interventions, or less frequent INR (International Normalized Ratio) monitoring among warfarin users in these regions. Environmental factors also contribute to this elevated risk [41, 42], as rural residents are often exposed to dry, dusty conditions or agricultural pollutants, which can irritate the nasal mucosa and increase the likelihood of nosebleeds. Furthermore, lower humidity in certain rural areas exacerbates nasal dryness, leading to mucosal damage and a higher incidence of epistaxis [43]. However, further studies in similar populations are necessary to validate these findings and provide a more comprehensive understanding of the risk factors involved. Hypertension has long been recognized as a significant risk factor for epistaxis [8, 9, 39]. In our study, hypertension emerged as one of the most prominent comorbidities associated with nasal bleeding, affecting 71.2% of the patients who experienced epistaxis. Multivariate analysis further identified hypertension as an independent predictor, with hypertensive patients showing a 3.14 times higher risk of developing epistaxis compared to non‐hypertensive individuals. This finding is consistent with epidemiological research, where multiple studies have demonstrated a strong association between hypertension and epistaxis. For example, a meta‐analysis conducted by Jin Min et al. in 2017, which included 10 studies, revealed an increased odds ratio for epistaxis in hypertensive patients (OR = 1.253; 95% CI: 1.080–1.453) [9]. These results reinforce the link between hypertension and an elevated risk of epistaxis. It is crucial to note that hypertension not only raises the likelihood of epistaxis but also prolongs the bleeding episodes, making them more difficult to control [44]. Therefore, this finding stresses the need for careful management of blood pressure in patients prone to nasal bleeding, especially in the patients undergoing anticoagulants/antiplatelet therapy. The increased risk of epistaxis in hypertensive patients is thought to be multifactorial. Chronic vascular damage has been proposed as a key pathophysiological mechanism linking hypertension to epistaxis. A postmortem study revealed degenerative fibrous changes in the nasal vessels of hypertensive patients, suggesting that long‐term high blood pressure contributes to structural damage in the vasculature [10]. Additionally, arterial hypertension may damage the vascular endothelial wall through oxidative stress [45]. Various histological changes, including the formation of atherosclerotic plaques, are common in hypertensive individuals, rendering blood vessels more fragile and prone to rupture [46]. One of the more intriguing findings is the strong association between congestive heart failure (CHF) and epistaxis, a link that is rarely discussed in the literature. For instance, in a retrospective cohort study conducted by Abric et al. [8] the risk of recurrent epistaxis was found to be 60% higher in heart failure patients compared to a control group (HR: 1.6; p < 0.01). Similarly, a study by Chhaban et al. [47] on elderly patients visiting the emergency department also reported a significant correlation between recurrent epistaxis and CHF. In our own study, CHF was identified as a potential risk factor for an increased likelihood of epistaxis (AOR: 2.38; p < 0.05). These findings suggest that the relationship between CHF and epistaxis should not be overlooked, and patients with CHF should be informed about the increased risk of experiencing recurrent nosebleeds. This emerging evidence underscores the importance of recognizing CHF as a contributing factor in the management of epistaxis. The proposed mechanism underlying the association between congestive heart failure (CHF) and epistaxis is primarily attributed to the heart's reduced capacity to effectively pump blood. In CHF, the diminished cardiac output results in fluid retention and increased venous pressure throughout the circulatory system, including the nasal vasculature [48]. This heightened venous pressure in the nasal passages leads to venous congestion, which in turn increases the vulnerability of blood vessels to rupture and subsequent bleeding. Another proposed explanation for the observed association between congestive heart failure (CHF) and recurrent epistaxis in our cohort could be the presence of undiagnosed hereditary hemorrhagic telangiectasia (HHT). HHT, a genetic disorder characterized by abnormal blood vessel formation, is associated with an increased risk of bleeding due to vascular fragility. There is a well‐established link between high‐output heart failure and HHT [49], which arises from the right‐to‐left shunting of blood, a hallmark feature of this condition. This shunting can weaken blood vessels, especially in the Kiesselbach area of the nasal septum, a region with a rich blood supply, leading to recurrent episodes of epistaxis. Another notable risk factor identified in our study was the use of traditional oral anticoagulants. Specifically, our findings revealed that the use of warfarin, a classical oral anticoagulant, was associated with a 2.38‐fold increase in the odds of experiencing epistaxis, even after controlling the effects of other significant factors in multivariate analysis. This result aligns with a growing body of research [19, 25, 26], that has consistently shown an increased risk of nosebleeds with the use of classical anticoagulant. Epidemiological studies have indicated a potential link between epistaxis and elevated INR [50]. In our study, however, only a limited number of patients had INR data available, making it impossible to include this factor in the analysis. Therefore, our study stresses the need for greater recognition of these issues and the establishment of improved INR monitoring facilities both in hospitals and within the community. Such improvements could help reduce the incidence of significant epistaxis in patients receiving warfarin therapy. In contrast, direct oral anticoagulants (DOACs) in our study, including Dabigatran, Rivaroxaban, and Apixaban, did not show a significant association with epistaxis, aligning the finding of the earlier study [26]. Since newer anticoagulants target specific clotting pathways (e.g., Factor Xa or thrombin) more precisely than older agents like warfarin, they may lead to a reduced risk of bleeding from mucosal surfaces, such as the nasal mucosa. This lack of epistaxis can suggest that these drugs have a more favorable bleeding profile compared to classical OAC, and could be a choice for long‐term use. However, the small sample size of patients on DOACs in this study limits the ability to draw definitive conclusions about their safety in relation to epistaxis. Further research is warranted to explore the comparative safety of DOACs vs. warfarin in the Nepali population, particularly as the use of DOACs becomes more widespread. In contrast to warfarin, our study did not find aspirin use to be a statistically significant risk factor for epistaxis. The impact of aspirin on nosebleeds has been subject to conflicting findings in the literature. For example, a case‐control study by Rainsbury et al. reported a significantly increased risk of epistaxis associated with the use of aspirin or clopidogrel [51]. However, this contrasts with the findings of Abrich et al. [8], who observed that aspirin and clopidogrel did not appear to increase the risk of epistaxis. These conflicting results highlight the need for further research to clarify the relationship between aspirin use and epistaxis risk. There has been conflicting evidence regarding the relationship between clopidogrel use and the risk of epistaxis [8, 51]. In our study, while clopidogrel did not emerge as an independent predictor of epistaxis, the prevalence of epistaxis was significantly lower in individuals receiving clopidogrel compared to those not undergoing clopidogrel therapy. This finding is unexpected given clopidogrel's known antiplatelet effects, which typically increase the risk of bleeding. One possible explanation could be that patients prescribed clopidogrel may have been more closely monitored and managed to mitigate bleeding risks, including nasal bleeding. Additionally, preventive measures, such as nasal humidification or avoidance of environmental triggers, may have been more commonly recommended to patients on antiplatelet therapy, potentially reducing the occurrence of epistaxis. Further investigation into these protective factors and clinical practices is warranted to better understand this observed difference. Our study further examined the effect of combining aspirin with other anticoagulant or antiplatelet medications on epistaxis, but did not find a significant association with the risk of epistaxis. This contrasts with earlier studies, such as Abrich et al. [8], which demonstrated a significant link between dual therapy and an increased risk of epistaxis. These differing findings suggest the need for further research to clarify the impact of combined anticoagulant or antiplatelet therapy on epistaxis risk, as factors such as limited sample size in respective subgroup, patient's characteristics, and other factors may have influenced the outcomes in our study. The management approach to epistaxis varies depending on the severity, frequency, and underlying etiology of the bleeding, as well as patient‐specific factors, including age, comorbidities, and concurrent medications [52, 53]. In patients on anticoagulant or antiplatelet therapy, epistaxis can be more challenging to control, as these medications increase the risk of bleeding and decrease the efficacy of standard management approaches. One of the primary methods used in the management of epistaxis is nasal packing, which is a widely accepted and commonly used intervention for epistaxis, particularly in settings where resources are limited or when immediate control of bleeding is required [53]. In this study, a significant portion of cases did not require any intervention, suggesting that a considerable portion of epistaxis cases may be self‐limiting and can be addressed conservatively. The remaining portion was managed through nasal packing. The results align with existing literature that emphasizes the relative ease of application, cost‐effectiveness, and effectiveness of nasal packing as a first‐line treatment for moderate to severe cases in achieving hemostasis [53]. Although nasal packing remains a cornerstone of epistaxis management, further studies are warranted to identify its effective, particularly in anticoagulated patients or those with recurrent epistaxis. Limitations We acknowledge that this study has certain limitations, which could be addressed in future investigation. First, this was a single‐center hospital based study, which may limit the generalizability of the findings to other settings in Nepal. Second, the cross‐sectional design of the study does not allow for the establishment of causal relationships between risk factors and epistaxis. Additionally, there is a possibility of recall bias in the self‐reported episodes of epistaxis. Future studies could overcome these limitations by employing larger, multi‐center designs with longitudinal follow‐up to better assess the long‐term incidence of bleeding complications. We also acknowledge that elevated INR levels or concurrent NSAID, local nasal pathology may increase bleeding tendencies, while local nasal pathology and seasonal variations may contribute to differences in clinical presentation. However, these variables were not included in our analysis, as these variables were not consistently recorded for all patients. The absence of these factors may have introduced potential confounding, as they could independently affect both the exposure and outcome variables. Conclusion Our study revealed a notably high prevalence of epistaxis among patients undergoing antiplatelet or anticoagulant therapy, with the majority of cases demonstrating moderate severity. A slightly more than half of the epistaxis cases required no treatment, while nasal packing was the preferred method for managing the treated cases. Age, gender, living area, comorbid conditions, and the use of specific anticoagulants, particularly direct oral anticoagulants, were found to be closely associated with the likelihood of experiencing epistaxis. More specifically, advancing age emerged as a key factor, with older patients exhibiting a heightened risk of developing epistaxis. Male patients were also found to be more susceptible than their female counterparts. Furthermore, individuals residing in rural areas were at a significantly higher risk compared to those living in urban settings. Among the comorbid conditions examined, hypertension and congestive heart failure stood out as particularly influential in increasing the likelihood of experiencing epistaxis. Additionally, patients receiving warfarin therapy evolved as a potential risk factor associated with the elevated risk of experiencing epistaxis. These findings underscore the importance of regular monitoring and managing patients on antiplatelet or anticoagulant therapy, particularly those with the aforementioned risk factors, to mitigate the potential for epistaxis. For instance, if there are multiple bleeding sites or recurrent bleeding, which may suggest an underlying systemic condition such as hypertension, or anticoagulation, in such cases, relevant tests—such as a complete blood count, anticoagulant levels, prothrombin time, partial thromboplastin time, platelet count, and, when necessary, blood typing and cross‐matching—should be conducted and monitored [54, 55]. It is also advisable that clinicians should consider these associations when developing individualized treatment plans and provide appropriate counseling and interventions to minimize bleeding complications in high‐risk patient populations. Author Contributions Shiv Kumar Sah: investigation, writing – original draft, methodology, validation, software, formal analysis, project administration, supervision, resources. Ashok Kumar Gupta: conceptualization, investigation, methodology, writing – review and editing, software, formal analysis, resources, data curation. Sanjaya Acharya: visualization, validation, project administration, data curation, resources, investigation. Suraj Kumar Thakur: project administration, resources, data curation, writing – review and editing, investigation. Rajkumar Chaudhary: project administration, resources, data curation, writing – review and editing, investigation. Shiva Pandeya: resources, supervision, project administration, writing – review and editing, investigation. Arjun Budthapa: resources, supervision, project administration, visualization, writing – review and editing. Vijaya K. C.: writing – review and editing, software, methodology, supervision. Sajish Khadgi: writing – review and editing, methodology, supervision, data curation, investigation. Manjita Bajracharya: resources, supervision, data curation, writing – review and editing, investigation, methodology. Funding The authors have nothing to report. Disclosure The lead author, Shiv Kumar Sah, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File Acknowledgments We sincerely thank the Department of ENT and the Emergency Department of Tribhuvan University Teaching Hospital (TUTH) for their support in conducting this study. Special thanks to the medical and administrative staff who facilitated data collection and provided invaluable assistance throughout the research process. We are particularly grateful to the patients who participated in this study, as their cooperation made this research possible. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Supporting File Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.